概括
在EGFR突变非小细胞肺癌患者中,奥西默蒂尼布显著提高了整体存活率. 在ADAURA试验中,辅助性奥西默蒂尼布可将死亡风险降低51%.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 非小细胞肺癌 (NSCLC) 是癌症死亡的主要原因.
- 表皮生长因子受体 (EGFR) 突变是NSCLC患者的一个子集的关键驱动因素.
- 辅助疗法旨在消除残留的癌细胞并防止复发.
研究的目的:
- 报告ADAURA试验的最终总生存 (OS) 结果.
- 评估辅助性奥西默蒂尼布在切除EGFR突变NSCLC的患者中的疗效.
主要方法:
- ADAURA试验是一项随机,双盲,安慰剂控制的研究.
- 患有IB,II或IIIA阶段EGFR突变NSCLC的患者在完全切除瘤后接受辅助性奥西默蒂尼布或安慰剂.
- 总体存活率是主要的终点.
主要成果:
- 与安慰剂相比,奥西默蒂尼布显示死亡风险降低了51%.
- 在5年后,在接受奥西默提尼布的患者中,生存率为85%,对照组在II/IIIA阶段的疾病中为73%.
- 当包括IB期患者时,观察到类似的生存益处.
结论:
- 辅助性奥西默提尼布显著改善了切除EGFR突变NSCLC的患者的整体存活率.
- 奥西默提尼布是一种高效的治疗方法,可降低这种患者群体的死亡率.
- 这些发现支持使用奥西默蒂尼布作为EGFR突变NSCLC的辅助剂.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
